Literature DB >> 29589184

Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?

J C Yugar-Toledo1, V Brunelli2, J F Vilela-Martin1, A Fattori2, H Moreno3.   

Abstract

PURPOSE OF REVIEW: Resistant hypertension (RHTN) is a condition in which besides the antihypertensive therapy using at least three different drugs (including a diuretics), brachial blood pressure does not reach the target (e.g., 140/90 mmHg). RECENT
FINDINGS: Despite the diversity of clinical presentations, we divide RHTN in two major groups according to blood pressure and number of drugs taken: controlled (C-RHTN) and uncontrolled (UC-RHTN) resistant hypertension, with refractory hypertension (RfHTN) included in the latter subgroup. Both C-RHTN and UC-RHTN are heterogenic and complex syndromes. To better approach this matter, the some pathophysiological mechanisms (increased volemia, hyperactivity, plasma cortisol, adipocitokines, and other pro-inflammatory factors), have a pivotal clinical role. Some features (African ethnic, obesity, age > 60, LV hypertrophy, and vascular stiffness) increase the risk of refractoriness as well as worst prognosis. Based on increased target organ damage, cardiovascular risk and events will be addressed in this review. Our conclusion is that although both C-RHTN and UC-RHTN are extreme phenotypes of hard-to-control BP, some mechanisms of the disease and clinical expressions are distinct. According to these differences, "UC-RHTN and C-RHTN are not in the same bag."

Entities:  

Keywords:  C-RHTN; Controlled hypertension; RHTN; Refractory hypertension; Resistant hypertension; RfHTN; UC-RHTN; Uncontrolled resistant hypertension

Mesh:

Substances:

Year:  2018        PMID: 29589184     DOI: 10.1007/s11906-018-0825-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  50 in total

1.  Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness.

Authors:  L C Martins; V N Figueiredo; T Quinaglia; L Boer-Martins; J C Yugar-Toledo; J F V Martin; C Demacq; E Pimenta; D A Calhoun; H Moreno
Journal:  J Hum Hypertens       Date:  2010-10-07       Impact factor: 3.012

Review 2.  Refractory versus resistant hypertension.

Authors:  Mohammed Siddiqui; David A Calhoun
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-01       Impact factor: 2.894

3.  Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension.

Authors:  Rodrigo P Pedrosa; Luciano F Drager; Carolina C Gonzaga; Marcio G Sousa; Lílian K G de Paula; Aline C S Amaro; Celso Amodeo; Luiz A Bortolotto; Eduardo M Krieger; T Douglas Bradley; Geraldo Lorenzi-Filho
Journal:  Hypertension       Date:  2011-10-03       Impact factor: 10.190

4.  Impact of baroreflex activation therapy on renal function--a pilot study.

Authors:  Manuel Wallbach; Luca-Yves Lehnig; Charlotte Schroer; Gerd Hasenfuss; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  Am J Nephrol       Date:  2014-10-29       Impact factor: 3.754

Review 5.  Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels.

Authors:  Eric K Judd; David A Calhoun; David G Warnock
Journal:  Semin Nephrol       Date:  2014       Impact factor: 5.299

6.  Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes.

Authors:  Juan Carlos Yugar-Toledo; José Fernando Vilela Martin; José Eduardo Krieger; Alexandre C Pereira; Caroline Demacq; Otávio Rizzi Coelho; Eduardo Pimenta; David A Calhoun; Heitor Moreno Júnior
Journal:  DNA Cell Biol       Date:  2011-03-27       Impact factor: 3.311

Review 7.  Salt, the renin-angiotensin-aldosterone system and resistant hypertension.

Authors:  Tatsuo Shimosawa
Journal:  Hypertens Res       Date:  2013-08       Impact factor: 3.872

Review 8.  Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials.

Authors:  Chunbin Wang; Bo Xiong; Jing Huang
Journal:  Heart Lung Circ       Date:  2016-04-11       Impact factor: 2.975

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Deregulation of Soluble Adhesion Molecules in Resistant Hypertension and Its Role in Cardiovascular Remodeling.

Authors:  Ana Paula de Faria; Alessandra Mileni Versuti Ritter; Andréa Rodrigues Sabbatini; Nathália Batista Corrêa; Veridiana Brunelli; Rodrigo Modolo; Heitor Moreno
Journal:  Circ J       Date:  2016-04-13       Impact factor: 2.993

View more
  3 in total

Review 1.  Pseudo and resistant hypertension: A chaotic perspective.

Authors:  Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-04-25       Impact factor: 2.885

Review 2.  Resistant Hypertension: Time to Consider the Best Fifth Anti-Hypertensive Treatment.

Authors:  Andrea Pio-Abreu; Luciano F Drager
Journal:  Curr Hypertens Rep       Date:  2018-06-16       Impact factor: 5.369

3.  Brazilian Position Statement on Resistant Hypertension - 2020.

Authors:  Juan Carlos Yugar-Toledo; Heitor Moreno Júnior; Miguel Gus; Guido Bernardo Aranha Rosito; Luiz César Nazário Scala; Elizabeth Silaid Muxfeldt; Alexandre Alessi; Andrea Araújo Brandão; Osni Moreira Filho; Audes Diógenes de Magalhães Feitosa; Oswaldo Passarelli Júnior; Dilma do Socorro Moraes de Souza; Celso Amodeo; Weimar Kunz Sebba Barroso; Marco Antônio Mota Gomes; Annelise Machado Gomes de Paiva; Eduardo Costa Duarte Barbosa; Roberto Dischinger Miranda; José Fernando Vilela-Martin; Wilson Nadruz Júnior; Cibele Isaac Saad Rodrigues; Luciano Ferreira Drager; Luiz Aparecido Bortolotto; Fernanda Marciano Consolim-Colombo; Márcio Gonçalves de Sousa; Flávio Antonio de Oliveira Borelli; Sérgio Emanuel Kaiser; Gil Fernando Salles; Maria de Fátima de Azevedo; Lucélia Batista Neves Cunha Magalhães; Rui Manoel Dos Santos Póvoa; Marcus Vinícius Bolívar Malachias; Armando da Rocha Nogueira; Paulo César Brandão Veiga Jardim; Thiago de Souza Veiga Jardim
Journal:  Arq Bras Cardiol       Date:  2020 May-Jun       Impact factor: 2.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.